Company intelligence / Profile preview

Avilex Pharma

Ownership: Private
Development stage: Other

Overview

Successfully completed Phase 1 clinical trial for lead candidate AVLX-144, which was well-tolerated with no noteworthy safety issues. The company is now advancing to Phase 2 clinical trials.

Therapeutic areas: CardiovascularNeurology
Modalities: Peptide-like drugsDimeric peptidesCyclic peptides
Industry: Biotech

Drug pipeline

2 assets

AVLX-144

1 more asset in the full pipeline.

Partnerships

Simcere Pharmaceutical Group Ltd (strategic partnership for Greater China)

Beyond the preview

Go deeper on Avilex Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avilex Pharma.